Tuesday, October 13, 2026

Nikkei 225 Bullish Momentum With A 3% Jump In The Last 5 Sessions

ViaNews Editorial Team

November 9, 2023

Nikkei 225 Bullish Momentum With A 3% Jump In The Last 5 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 3.1% for the last 5 sessions. At 09:08 EST on Thursday, 9 November, Nikkei 225 (N225) is $32,580.29.

Concerning Nikkei 225's yearly highs and lows, it's 26.96% up from its 52-week low and 3.53% down from its 52-week high.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be overbought (>=80).

News about

  • According to DailyForex on Tuesday, 7 November, "In essence, the S&P 500 effectively functions as an ETF comprising the most dominant mega-cap entities in the realm of Wall Street. "
  • According to FXStreet on Tuesday, 7 November, "That reflects the overall performance of the market, as the S&P 500 was down 3.8% in the third quarter, while Buffett's largest holding, Apple (NASDAQ: AAPL), which makes up some 47% of the portfolio, dropped 11% in the quarter."
  • According to MarketWatch on Tuesday, 7 November, "The stock has fallen 16% in the year to date, while the S&P 500 has gained 13.7%."
  • According to MarketWatch on Tuesday, 7 November, "The stock has tumbled 57.3% over the past three months through Monday, while the iShares Biotechnology ETF has lost 5.6% and the S&P 500 has slipped 3.4%."
  • According to MarketWatch on Tuesday, 7 November, "The stock is now up 34.9% in 2023, compared to a 13.5% year-to-date rise by the S&P 500 SPX."

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com